{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:21Z","timestamp":1790286921390,"version":"4.1.0"},"reference-count":138,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>While several medications are known to induce dermatomyositis (DM), most existing studies are case reports or small case series from a single institution. There is also limited information on DM induced by immune checkpoint inhibitors, which are increasingly used in oncologic therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To characterize causes and clinical presentation of drug-induced DM based on the current literature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Evidence Review<\/jats:title><jats:p>A systematic review was performed in PubMed according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.equator-network.org\/reporting-guidelines\/prisma\/\">PRISMA<\/jats:ext-link>) reporting guidelines, from inception to August 22, 2022. Articles meeting preestablished inclusion criteria (written in English and classified as original articles, case reports, literature reviews, and observation letters) were selected and data abstracted. Articles that met the scope of the review were also added from reference lists. When possible, study results were quantitatively combined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>In 134 studies (114 from the literature search and 20 additional studies pulled from reference lists) describing 165 cases, 88 patients (53.3%) were female, and the median (IQR) age was 61 (49-69) years. Among the cases of drug-induced DM, the most common associated medications were hydroxyurea (50 [30.3%]), immune checkpoint inhibitors (27 [16.4%]), statins (22 [13.3%]), penicillamine (10 [6.1%]), and tumor necrosis factor inhibitors (10 [6.1%]). Histopathologic testing, when undertaken, helped establish the diagnosis. There was a median (IQR) of 60 (21-288) days between drug initiation and drug-induced DM onset. History of cancer was reported in 85 cases (51.6%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>In this systematic review, drug-induced DM was associated with multiple types of medications, including chemotherapies and immunotherapies. It is essential that dermatologists promptly recognize and diagnose drug-induced DM so that they can guide management to minimize interruption of therapy when possible.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.5418","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T16:00:54Z","timestamp":1704902454000},"page":"210","source":"Crossref","is-referenced-by-count":17,"title":["Causes and Clinical Presentation of Drug-Induced Dermatomyositis"],"prefix":"10.1001","volume":"160","author":[{"given":"Sahar","family":"Caravan","sequence":"first","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Stanford University School of Medicine, Redwood City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9388","key":"drv230005r1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis.","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"drv230005r2","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s11926-022-01070-w","article-title":"Update on cutaneous signs to assist in the diagnosis of dermatomyositis.","volume":"24","author":"El-Banna","year":"2022","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"drv230005r3","first-page":"359","article-title":"Current concepts and advances in dermatomyositis: a dermatological perspective.","volume":"41","author":"Lim","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"drv230005r4","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2340\/0001555577490","article-title":"A case of dermatomyositis triggered by tegafur.","volume":"77","author":"Akiyama","year":"1997","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"drv230005r5","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/ddg.v19.7","article-title":"Paclitaxel-related eruption mimicking dermatomyositis.","volume":"19","author":"Alam\u00f3n-Reig","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"drv230005r6","first-page":"196","article-title":"Carbimazole-induced juvenile dermatomyositis.","volume":"158","author":"Alvarez","year":"2008","journal-title":"Br J Dermatol"},{"issue":"3","key":"drv230005r7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/ced.2012.37.issue-3","article-title":"Possible zoledronic acid-induced dermatomyositis.","volume":"37","author":"Apalla","year":"2012","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"drv230005r8","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1093\/rheumatology\/keaa832","article-title":"Anti-TIF1? antibody-positive dermatomyositis in a 15-year-old boy with Epstein-Barr virus-related nasopharyngeal cancer receiving nivolumab.","volume":"60","author":"Asano","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"drv230005r9","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/bjd.1996.134.issue-6","article-title":"Pseudo-dermatomyositis induced by long-term hydroxyurea therapy: report of two cases.","volume":"134","author":"Bahadoran","year":"1996","journal-title":"Br J Dermatol"},{"issue":"5","key":"drv230005r10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.21037\/atm","article-title":"Environmental triggers of dermatomyositis: a narrative review.","volume":"9","author":"Bax","year":"2021","journal-title":"Ann Transl Med"},{"issue":"1","key":"drv230005r11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1212\/WNL.32.1.91","article-title":"Ipecac-induced myopathy simulating dermatomyositis.","volume":"32","author":"Bennett","year":"1982","journal-title":"Neurology"},{"key":"drv230005r12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejca.2018.08.021","article-title":"Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.","volume":"104","author":"Berger","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"drv230005r13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00296-017-3821-3","article-title":"Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review.","volume":"38","author":"Borges","year":"2018","journal-title":"Rheumatol Int"},{"issue":"3","key":"drv230005r14","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.jaad.2020.10.054","article-title":"De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: a retrospective analysis.","volume":"84","author":"Bui","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"drv230005r15","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3899\/jrheum.091413","article-title":"Dermatomyositis during adalimumab therapy for rheumatoid arthritis.","volume":"37","author":"Brunasso","year":"2010","journal-title":"J Rheumatol"},{"issue":"5","key":"drv230005r16","first-page":"995","article-title":"Penicillamine induced polymyositis and dermatomyositis.","volume":"14","author":"Carroll","year":"1987","journal-title":"J Rheumatol"},{"issue":"7-8","key":"drv230005r17","first-page":"462","article-title":"Life-threatening flare of an underlying paraneoplastic dermatomyositis in a patient with lung adenocarcinoma treated with anti-PD-1 pembrolizuma.","volume":"77","author":"Chauveheid","year":"2022","journal-title":"Rev Med Liege"},{"issue":"2","key":"drv230005r18","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.jaad.2013.10.025","article-title":"Dermatomyositis associated with capecitabine in the setting of malignancy.","volume":"70","author":"Chen","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"drv230005r19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2021.06.031","article-title":"Rare cutaneous toxicity of immune checkpoint inhibitors: a case of durvalumab-induced dermatomyositis.","volume":"155","author":"Coustal","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"drv230005r20","first-page":"397","article-title":"Dermatomyositis-like syndrome associated with phenylbutazone therapy.","volume":"14","author":"Curran","year":"1987","journal-title":"J Rheumatol"},{"issue":"3","key":"drv230005r21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1067\/mjd.2003.74","article-title":"Hydroxyurea-induced dermatomyositis-like eruption.","volume":"48","author":"Dacey","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"drv230005r22","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/j.jaad.2013.11.012","article-title":"Dermatomyositis associated with anti-tumor necrosis factor therapy in a patient with psoriasis.","volume":"70","author":"Dicaro","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"drv230005r23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/BF02826219","article-title":"Dermatomyositis after interferon alpha treatment.","volume":"17","author":"Dietrich","year":"2000","journal-title":"Med Oncol"},{"issue":"11","key":"drv230005r24","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1177\/088307389801301111","article-title":"Phenytoin-induced dermatomyositis: case report and literature review.","volume":"13","author":"Dimachkie","year":"1998","journal-title":"J Child Neurol"},{"issue":"4","key":"drv230005r25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1517\/14740338.7.4.421","article-title":"Activity of certain drugs in inducing of inflammatory myopathies with cutaneous manifestations.","volume":"7","author":"Dourmishev","year":"2008","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"drv230005r26","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/j.jaad.2013.07.017","article-title":"Acute autoimmune thrombocytopenia and worsening of dermatomyositis after administration of clarithromycin.","volume":"69","author":"Drago","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"drv230005r27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.25259\/IJDVL","article-title":"Immunotherapy-intensified paraneoplastic dermatomyositis.","volume":"88","author":"Estenaga","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"drv230005r28","doi-asserted-by":"publisher","DOI":"10.1111\/dth.2017.30.issue-4","article-title":"Simvastatin-associated dermatomyositis.","volume":"30","author":"Fania","year":"2017","journal-title":"Dermatol Ther"},{"issue":"1","key":"drv230005r29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/ard.36.1.94","article-title":"Dermatomyositis complicating penicillamine treatment.","volume":"36","author":"Fernandes","year":"1977","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"drv230005r30","doi-asserted-by":"publisher","first-page":"R666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"drv230005r31","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/00124743-200202000-00011","article-title":"Drug-induced amyopathic dermatomyositis.","volume":"8","author":"Flores-Su\u00e1rez","year":"2002","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"drv230005r32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jdcr.2018.03.009","article-title":"Drug-induced dermatomyositis after lacosamide: a case report.","volume":"4","author":"Gaffney","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"4","key":"drv230005r33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/mus.v41:4","article-title":"Minocycline-induced dermatomyositis.","volume":"41","author":"Geddes","year":"2010","journal-title":"Muscle Nerve"},{"issue":"1","key":"drv230005r34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000248390","article-title":"Dermatomyositis-like syndrome induced by nonsteroidal anti-inflammatory agents.","volume":"178","author":"Grob","year":"1989","journal-title":"Dermatologica"},{"issue":"6","key":"drv230005r35","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/art.v55:6","article-title":"Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor.","volume":"55","author":"Hall","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"drv230005r36","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/0002-9343(84)90371-1","article-title":"Penicillamine-induced myositis: observations and unique features in two patients and review of the literature.","volume":"77","author":"Halla","year":"1984","journal-title":"Am J Med"},{"issue":"2","key":"drv230005r37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/08258597211030382","article-title":"Dermatomyositis identified during palliative care management for chemotherapy-associated pain: a case report.","volume":"37","author":"Hamada","year":"2022","journal-title":"J Palliat Care"},{"issue":"6","key":"drv230005r38","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/imj.1995.25.issue-6","article-title":"Dermatomyositis with lung involvement in a patient treated with simvastatin.","volume":"25","author":"Hill","year":"1995","journal-title":"Aust N Z J Med"},{"issue":"4","key":"drv230005r39","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.v9.4","article-title":"Anti-TIF1? antibody-positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers.","volume":"9","author":"Imai","year":"2021","journal-title":"Respirol Case Rep"},{"issue":"1","key":"drv230005r40","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/bjd.2009.161.issue-1","article-title":"Simvastatin-induced amyopathic dermatomyositis.","volume":"161","author":"Inhoff","year":"2009","journal-title":"Br J Dermatol"},{"issue":"8","key":"drv230005r41","doi-asserted-by":"publisher","DOI":"10.5070\/D3208023534","article-title":"Hydroxyurea-induced amyopathic dermatomyositis presenting with heliotrope erythema.","volume":"20","author":"Ito","year":"2014","journal-title":"Dermatol Online J"},{"issue":"3","key":"drv230005r42","first-page":"131","article-title":"Dermatomyositis-like eruption induced by hydroxyurea: a case report.","volume":"18","author":"Janerowicz","year":"2009","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"4","key":"drv230005r43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11926-019-0811-3","article-title":"Immune checkpoint inhibitor-induced myositis: a case report and literature review.","volume":"21","author":"Kadota","year":"2019","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"drv230005r44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1001\/archdermatol.2010.11","article-title":"Hydroxyurea-associated dermatomyositis-like eruption demonstrating abnormal epidermal p53 expression: a potential premalignant manifestation of chronic hydroxyurea and UV radiation exposure.","volume":"146","author":"Kalajian","year":"2010","journal-title":"Arch Dermatol"},{"issue":"6","key":"drv230005r45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2217\/imt-2020-0309","article-title":"A case of successful pembrolizumab rechallenge in a patient with non-small-cell lung cancer and grade 3 dermatomyositis.","volume":"13","author":"Kartolo","year":"2021","journal-title":"Immunotherapy"},{"issue":"11","key":"drv230005r46","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/jde.2014.41.issue-11","article-title":"Antitumor necrosis factor alpha inhibitor-induced dermatomyositis and interstitial lung disease with anti-PL12 autoantibody: signs of antisynthetase syndrome.","volume":"41","author":"Kato","year":"2014","journal-title":"J Dermatol"},{"issue":"2","key":"drv230005r47","first-page":"195","article-title":"Paraneoplastic dermatomyositis triggered and exacerbated by oral 5-fluorouracil administration.","volume":"18","author":"Kawachi","year":"2008","journal-title":"Eur J Dermatol"},{"issue":"2","key":"drv230005r48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/rheumatology\/33.2.199","article-title":"Simvastatin-associated dermatomyositis.","volume":"33","author":"Khattak","year":"1994","journal-title":"Br J Rheumatol"},{"issue":"7","key":"drv230005r49","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/archdermatol.2010.142","article-title":"Tumor necrosis factor inhibitor-associated dermatomyositis.","volume":"146","author":"Klein","year":"2010","journal-title":"Arch Dermatol"},{"issue":"8","key":"drv230005r50","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/ced.2016.41.issue-8","article-title":"Dermatitis, nonmelanoma skin cancer and leg ulcers.","volume":"41","author":"Koch","year":"2016","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"drv230005r51","first-page":"341","article-title":"Dermatopolymyositis induced by D-penicillamine in rheumatoid polyarthritis: apropos of 1 case with review of the literature.","volume":"59","author":"Kolsi","year":"1992","journal-title":"Rev Rhum Mal Osteoartic"},{"issue":"3","key":"drv230005r52","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/CMR.0000000000000642","article-title":"Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.","volume":"30","author":"Kosche","year":"2020","journal-title":"Melanoma Res"},{"issue":"15","key":"drv230005r53","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2169\/internalmedicine.9381-17","article-title":"Advanced lung adenocarcinoma with nivolumab-associated dermatomyositis.","volume":"57","author":"Kudo","year":"2018","journal-title":"Intern Med"},{"issue":"10","key":"drv230005r54","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1111\/ijd.2006.45.issue-10","article-title":"Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.","volume":"45","author":"Kuwano","year":"2006","journal-title":"Int J Dermatol"},{"issue":"2","key":"drv230005r55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CND.0000000000000329","article-title":"What is in the myopathy literature?","volume":"22","author":"Lacomis","year":"2020","journal-title":"J Clin Neuromuscul Dis"},{"issue":"4","key":"drv230005r56","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s13555-020-00396-6","article-title":"Toripalimab-induced dermatomyositis in a patient with metastatic melanoma.","volume":"10","author":"Lin","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"drv230005r57","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1001\/jamadermatol.2013.5220","article-title":"Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis.","volume":"149","author":"Liu","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"4","key":"drv230005r58","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3109\/03009748309099739","article-title":"Penicillamine-induced dermatomyositis: a case history.","volume":"12","author":"Lund","year":"1983","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"drv230005r59","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/ajd.1979.20.issue-1","article-title":"Systemic lupus erythematosus\u2014dermatomyositis induced by sulphacetamide eye drops.","volume":"20","author":"Mackie","year":"1979","journal-title":"Australas J Dermatol"},{"issue":"1","key":"drv230005r60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cup.2008.35.issue-1","article-title":"Terbinafine-induced dermatomyositis: a case report and literature review of drug-induced dermatomyositis.","volume":"35","author":"Magro","year":"2008","journal-title":"J Cutan Pathol"},{"issue":"3","key":"drv230005r61","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bjd.v181.3","article-title":"Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.","volume":"181","author":"Marano","year":"2019","journal-title":"Br J Dermatol"},{"issue":"4","key":"drv230005r62","first-page":"536","article-title":"Pseudo-dermatomyositis as a complication of hydroxyurea therapy.","volume":"18","author":"Marie","year":"2000","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"drv230005r63","doi-asserted-by":"publisher","DOI":"10.5070\/D3268049887","article-title":"Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.","volume":"26","author":"Messer","year":"2020","journal-title":"Dermatol Online J"},{"issue":"11","key":"drv230005r64","doi-asserted-by":"publisher","DOI":"10.5070\/D32311037268","article-title":"A patient case highlighting the myriad of cutaneous adverse effects of prolonged use of hydroxyurea.","volume":"23","author":"Neill","year":"2017","journal-title":"Dermatol Online J"},{"issue":"1","key":"drv230005r65","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jdv.2007.21.issue-1","article-title":"Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.","volume":"21","author":"No\u00ebl","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"drv230005r66","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/S0002-9343(01)00711-2","article-title":"Atorvastatin-induced dermatomyositis.","volume":"110","author":"No\u00ebl","year":"2001","journal-title":"Am J Med"},{"issue":"5","key":"drv230005r67","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/ijd.2012.51.issue-5","article-title":"Hydroxyurea-induced dermatomyositis: true amyopathic dermatomyositis or dermatomyositis-like eruption?","volume":"51","author":"Nofal","year":"2012","journal-title":"Int J Dermatol"},{"issue":"15","key":"drv230005r68","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019741","article-title":"A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors.","volume":"99","author":"Ohira","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"drv230005r69","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10637-020-00974-7","article-title":"Anti-transcriptional intermediary factor 1-? antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: a case report.","volume":"39","author":"Osaki","year":"2021","journal-title":"Invest New Drugs"},{"issue":"6","key":"drv230005r70","first-page":"586","article-title":"Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycythemia vera.","volume":"12","author":"Oskay","year":"2002","journal-title":"Eur J Dermatol"},{"issue":"24","key":"drv230005r71","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.2169\/internalmedicine.9194-17","article-title":"Occurrence of dermatomyositis immediately after mastectomy subsequent to severe chemotherapeutic drug eruption.","volume":"56","author":"Otsuka","year":"2017","journal-title":"Intern Med"},{"issue":"7","key":"drv230005r72","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s00296-017-3658-9","article-title":"Atorvastatin-induced dermatomyositis.","volume":"37","author":"Oztas","year":"2017","journal-title":"Rheumatol Int"},{"issue":"1","key":"drv230005r73","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.atherosclerosis.2011.11.005","article-title":"Statins as a possible cause of inflammatory and necrotizing myopathies.","volume":"222","author":"Padala","year":"2012","journal-title":"Atherosclerosis"},{"issue":"3","key":"drv230005r74","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/bjd.2006.154.issue-3","article-title":"Omeprazole-induced dermatomyositis.","volume":"154","author":"Pan","year":"2006","journal-title":"Br J Dermatol"},{"issue":"4","key":"drv230005r75","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.amjms.2020.05.011","article-title":"Dermatomyositis developed after exposure to Epstein-Barr virus infection and antibiotics use.","volume":"360","author":"Peravali","year":"2020","journal-title":"Am J Med Sci"},{"issue":"2","key":"drv230005r76","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/03009747809098847","article-title":"Penicillamine-induced polymyositis-dermatomyositis.","volume":"7","author":"Petersen","year":"1978","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"drv230005r77","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/jamadermatol.2017.3222","article-title":"A violaceous, photodistributed cutaneous eruption and leg ulcer in a woman with essential thrombocytosis.","volume":"154","author":"Platto","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"8","key":"drv230005r78","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/CJI.0000000000000380","article-title":"Role of IVIG in the treatment of autoimmune conditions with concurrent immune checkpoint inhibitors for metastatic cancer.","volume":"44","author":"Punekar","year":"2021","journal-title":"J Immunother"},{"issue":"1","key":"drv230005r79","first-page":"192","article-title":"Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis.","volume":"39","author":"Riolo","year":"2012","journal-title":"J Rheumatol"},{"issue":"3","key":"drv230005r80","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1046\/j.1468-3083.2000.00061-6.x","article-title":"Dermatomyositis-like eruption following hydroxyurea therapy.","volume":"14","author":"Rocamora","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"853","key":"drv230005r81","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/pgmj.72.853.694","article-title":"Lovastatin-associated dermatomyositis.","volume":"72","author":"Rodriguez-Garcia","year":"1996","journal-title":"Postgrad Med J"},{"issue":"3","key":"drv230005r82","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/BF00442147","article-title":"Familial occurrence of dermatomyositis and progressive scleroderma after injection of a local anaesthetic for dental treatment.","volume":"143","author":"Rose","year":"1985","journal-title":"Eur J Pediatr"},{"issue":"12","key":"drv230005r83","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1046\/j.1365-4362.2002.01349.x","article-title":"Dermatomyositis-like reaction induced by chemotherapeutical agents.","volume":"41","author":"Ruiz-Genao","year":"2002","journal-title":"Int J Dermatol"},{"issue":"5","key":"drv230005r84","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1136\/ard.2007.075523","article-title":"Increased exposure to statins in patients developing chronic muscle diseases: a 2-year retrospective study.","volume":"67","author":"Sailler","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"drv230005r85","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s12094-019-02214-8","article-title":"Safety and efficacy of PD-1\/PD-L1 blockade in patients with preexisting antinuclear antibodies.","volume":"22","author":"Sakakida","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"drv230005r86","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/ijp.IJP_356_18","article-title":"A case of capecitabine-induced dermatomyositis.","volume":"50","author":"Saraswat","year":"2018","journal-title":"Indian J Pharmacol"},{"issue":"9","key":"drv230005r87","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJM199208273270919","article-title":"Pravastatin-associated inflammatory myopathy.","volume":"327","author":"Schalke","year":"1992","journal-title":"N Engl J Med"},{"issue":"5","key":"drv230005r88","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.jaad.2008.05.034","article-title":"Dermatomyositis induced by drug therapy: a review of case reports.","volume":"59","author":"Seidler","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"drv230005r89","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jaad.2008.02.033","article-title":"Amyopathic dermatomyositis resembling stasis dermatitis.","volume":"59","author":"Seidler","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"drv230005r90","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/bjd.1995.133.issue-3","article-title":"Hydroxyurea-induced dermatomyositis-like eruption.","volume":"133","author":"Senet","year":"1995","journal-title":"Br J Dermatol"},{"issue":"2","key":"drv230005r91","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"9","key":"drv230005r92","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00296-014-2984-4","article-title":"Dermatomyositis as a complication of interferon-a therapy: a case report and review of the literature.","volume":"34","author":"Shiba","year":"2014","journal-title":"Rheumatol Int"},{"issue":"1","key":"drv230005r93","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13256-019-2105-9","article-title":"Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.","volume":"13","author":"Shibata","year":"2019","journal-title":"J Med Case Rep"},{"issue":"6","key":"drv230005r94","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2340\/0001555559543544","article-title":"Dermatomyositis induced by penicillamine.","volume":"59","author":"Simpson","year":"1979","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"drv230005r95","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/archderm.144.10.1341","article-title":"Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.","volume":"144","author":"Somani","year":"2008","journal-title":"Arch Dermatol"},{"issue":"8","key":"drv230005r96","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/art.v74.8","article-title":"Clinical images: hydroxyurea-induced dermatomyositis-like rash.","volume":"74","author":"Subhadarshani","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"drv230005r97","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1097\/DAD.0000000000000341","article-title":"Zoledronic acid-induced interface dermatitis.","volume":"37","author":"Succaria","year":"2015","journal-title":"Am J Dermatopathol"},{"issue":"2","key":"drv230005r98","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.alit.2017.09.001","article-title":"A case of clinically amyopathic dermatomyositis that developed during anti-TNF-a therapy for rheumatoid arthritis.","volume":"67","author":"Takata","year":"2018","journal-title":"Allergol Int"},{"key":"drv230005r99","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.930286","article-title":"A rare case of pembrolizumab-induced dermatomyositis in a patient with cancer of unknown primary origin.","volume":"22","author":"Takatsuki","year":"2021","journal-title":"Am J Case Rep"},{"issue":"4","key":"drv230005r100","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14387","article-title":"Dermatomyositis flare with immune checkpoint inhibitor therapy for melanoma.","volume":"13","author":"Thomas","year":"2021","journal-title":"Cureus"},{"issue":"12 pt 1","key":"drv230005r101","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/S0151-9638(05)79565-X","article-title":"Fluvastatin-induced dermatomyositis.","volume":"132","author":"Thual","year":"2005","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"drv230005r102","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1111\/ajd.2012.53.issue-4","article-title":"Drug-induced dermatomyositis after zoledronic acid.","volume":"53","author":"Tong","year":"2012","journal-title":"Australas J Dermatol"},{"issue":"4","key":"drv230005r103","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.4103\/jcrt.JCRT_209_19","article-title":"A case of trastuzumab-induced dermatomyositis.","volume":"17","author":"Trontzas","year":"2021","journal-title":"J Cancer Res Ther"},{"issue":"3","key":"drv230005r104","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1046\/j.1365-2230.1999.00443.x","article-title":"Dermatomyositis-like eruption and leg ulceration caused by hydroxyurea in a patient with psoriasis.","volume":"24","author":"Varma","year":"1999","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"drv230005r105","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/mus.v30:6","article-title":"Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake.","volume":"30","author":"Vasconcelos","year":"2004","journal-title":"Muscle Nerve"},{"issue":"10","key":"drv230005r106","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/rheumatology\/37.10.1135","article-title":"Alfuzosin-associated dermatomyositis.","volume":"37","author":"Vela-Casasempere","year":"1998","journal-title":"Br J Rheumatol"},{"issue":"2","key":"drv230005r107","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1046\/j.1365-2230.1998.00297.x","article-title":"Chronic hydroxyurea-induced dermatomyositis-like eruption with severe dermal elastosis.","volume":"23","author":"V\u00e9lez","year":"1998","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"drv230005r108","doi-asserted-by":"publisher","DOI":"10.1111\/dth.v35.6","article-title":"Dermatomyositis following COVID-19 vaccination.","volume":"35","author":"Venkateswaran","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"drv230005r109","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/ced.2019.44.issue-5","article-title":"Hydroxyurea-induced dermatomyositis koebnerizing at the site of previous shingles.","volume":"44","author":"Veraitch","year":"2019","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"drv230005r110","first-page":"573","article-title":"Drug induction in connective tissue diseases.","volume":"149","author":"Verdelli","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"issue":"3","key":"drv230005r111","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ijd.v59.3","article-title":"Statin-induced dermatomyositis for the practicing dermatologist: a review of the literature.","volume":"59","author":"Visconti","year":"2020","journal-title":"Int J Dermatol"},{"issue":"1","key":"drv230005r112","first-page":"120","article-title":"Dermatomyositis, pembrolizumab, and squamous cell carcinoma of the lung.","volume":"34","author":"Wiggins","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"2","key":"drv230005r113","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/ijd.1991.30.issue-2","article-title":"Cutaneous problems with drug therapy in rheumatoid arthritis.","volume":"30","author":"Wilson","year":"1991","journal-title":"Int J Dermatol"},{"issue":"12","key":"drv230005r114","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1177\/014107688007301213","article-title":"Dermatomyositis induced by penicillamine.","volume":"73","author":"Wojnarowska","year":"1980","journal-title":"J R Soc Med"},{"issue":"18","key":"drv230005r115","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.2169\/internalmedicine.6917-20","article-title":"Atezolizumab-associated dermatomyositis in advanced small-cell lung carcinoma.","volume":"60","author":"Yamaguchi","year":"2021","journal-title":"Intern Med"},{"issue":"3","key":"drv230005r116","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1111\/ajd.2012.53.issue-3","article-title":"Hydroxyurea induced dermatomyositis-like eruption.","volume":"53","author":"Zappala","year":"2012","journal-title":"Australas J Dermatol"},{"key":"drv230005r117","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.02.2011.3832","article-title":"Simvastatin-induced dermatomyositis in a 50-year-old man.","volume":"2011","author":"Zaraa","year":"2011","journal-title":"BMJ Case Rep"},{"issue":"7","key":"drv230005r118","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts).","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"4","key":"drv230005r119","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/ced.1980.5.issue-4","article-title":"Effects of hydroxyurea therapy on normal skin: a case report.","volume":"5","author":"Burns","year":"1980","journal-title":"Clin Exp Dermatol"},{"key":"drv230005r120","first-page":"4196","article-title":"L\u2019hydroxyuree responsable de lesions cutanees de type dermatomyosite rev.","volume":"11","author":"Chantereau","year":"1990","journal-title":"Med Int"},{"issue":"12","key":"drv230005r121","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omx063","article-title":"Aggressive and fatal statin-induced dermatomyositis: a case report.","volume":"2017","author":"Chemello","year":"2017","journal-title":"Oxf Med Case Reports"},{"issue":"2 pt 1","key":"drv230005r122","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0190-9622(97)70276-7","article-title":"Hydroxyurea dermopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea.","volume":"36","author":"Daoud","year":"1997","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"drv230005r123","first-page":"572","article-title":"Polymyositis exacerbated by gemfibrozil.","volume":"17","author":"Fusella","year":"1990","journal-title":"J Rheumatol"},{"issue":"6","key":"drv230005r124","first-page":"300","article-title":"Development of dermatomyositis in a woman with rheumatoid arthritis treated with leflunomide.","volume":"22","author":"G\u00f3mez Rodr\u00edguez","year":"2005","journal-title":"An Med Interna"},{"issue":"3","key":"drv230005r125","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/03009747909114454","article-title":"Dermatomyositis associated with BCG vaccination.","volume":"8","author":"K\u00e5ss","year":"1979","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"drv230005r126","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1001\/archderm.1975.01630140041002","article-title":"Skin changes secondary to hydroxyurea therapy.","volume":"111","author":"Kennedy","year":"1975","journal-title":"Arch Dermatol"},{"issue":"4","key":"drv230005r127","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies.","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"issue":"2","key":"drv230005r128","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1067\/S0190-9622(03)00427-4","article-title":"Hydroxyurea-induced melanonychia concomitant with a dermatomyositis-like eruption.","volume":"49","author":"Oh","year":"2003","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"drv230005r129","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00105-008-1637-5","article-title":"Simvastatin-induced dermatomyositis.","volume":"60","author":"Rasch","year":"2009","journal-title":"Hautarzt"},{"issue":"4 pt 1","key":"drv230005r130","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0190-9622(89)80274-9","article-title":"Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy.","volume":"21","author":"Richard","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"drv230005r131","first-page":"895","article-title":"Cutaneous lesions induced by long-term use of hydroxyurea.","volume":"111","author":"Sigal","year":"1984","journal-title":"Ann Dermatol Venereol"},{"issue":"4","key":"drv230005r132","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1046\/j.1365-2133.1998.02486.x","article-title":"Hydroxyurea dermopathy with a dermatomyositis-like eruption and a large leg ulcer.","volume":"139","author":"Suehiro","year":"1998","journal-title":"Br J Dermatol"},{"key":"drv230005r133","first-page":"492","article-title":"Dermatomyositis-like eruption complicating hydroxyurea therapy of myelogenous leukemia.","volume":"2","author":"Thomas","year":"1992","journal-title":"Eur J Dermatol"},{"issue":"2","key":"drv230005r134","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1365-2230.2001.00782.x","article-title":"Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia.","volume":"26","author":"Vassallo","year":"2001","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"drv230005r135","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1684\/ejd.2016.2770","article-title":"A case of drug-associated dermatomyositis following ipilimumab therapy.","volume":"26","author":"Yamaguchi","year":"2016","journal-title":"Eur J Dermatol"},{"issue":"10","key":"drv230005r136","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.jdcr.2018.08.006","article-title":"Wong-type dermatomyositis during anti-PD-1 therapy.","volume":"4","author":"Yu","year":"2018","journal-title":"JAAD Case Rep"},{"issue":"11","key":"drv230005r137","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.revmed.2005.07.005","article-title":"Pravastatin-induced dermatomyositis.","volume":"26","author":"Zuech","year":"2005","journal-title":"Rev Med Interne"},{"issue":"1","key":"drv230005r138","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020.","volume":"51","author":"Sun","year":"2021","journal-title":"Semin Arthritis Rheum"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2813821\/jamadermatology_caravan_2024_rv_230005_1707346924.63869.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T16:02:08Z","timestamp":1708531328000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2813821"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":138,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.5418","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}